These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 11398329)

  • 1. [A case of drug-resistant pulmonary tuberculosis treated successfully following disappearance of rifampicin resistance after 17 years' chemotherapy].
    Shigeto E; Murakami I; Yokosaki Y
    Kekkaku; 2001 Apr; 76(4):379-83. PubMed ID: 11398329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
    Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
    Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
    Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies on the problems of resistance to antituberculous drugs. II--1. Clinically applicable criteria of drug-resistance to rifampicin].
    Baba H
    Kekkaku; 1994 Jun; 69(6):387-96. PubMed ID: 8041057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
    Mizutani S
    Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapeutic regimens that were considered effective to cure pulmonary infection caused by Mycobacterium avium-Mycobacterium intracellulare complex].
    Tsukamura M
    Kekkaku; 1991 May; 66(5):375-80. PubMed ID: 1875580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
    Shah AR; Agarwal SK; Shah KV
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multidrug-resistant tuberculosis. 4. Treatment and prognosis of multidrug-resistant tuberculosis].
    Ogawara M; Sakatani M
    Kekkaku; 1998 Nov; 73(11):673-7. PubMed ID: 9866930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis].
    Iwanaga T; Yokota K; Kishikawa R; Ikeda T; Tsurutani H; Hirose T; Nishima S
    Kekkaku; 1997 Jan; 72(1):9-13. PubMed ID: 9038010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism].
    Mizutani H; Horiba M; Shindoh J; Kimura T; Son M; Wakahara K
    Kekkaku; 2001 Oct; 76(10):667-72. PubMed ID: 11712388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
    Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
    Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retreatment of pulmonary tuberculosis--duration of chemotherapy].
    Wada M; Seita A; Mori T; Ogata H; Sugie T; Sugita H
    Kekkaku; 1993 Jul; 68(7):469-78. PubMed ID: 8361115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of multidrug-resistant tuberculosis who acquired additional resistance to ethambutol before the result of the initial drug sensitivity test was reported].
    Wakabayashi K; Yano S; Kobayashi K; Kadowaki T; Kimura M; Ishikawa S; Ikeda T
    Kekkaku; 2010 Aug; 85(8):679-82. PubMed ID: 20845688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.
    Park SK; Kim CT; Song SD
    Int J Tuberc Lung Dis; 1998 Nov; 2(11):877-84. PubMed ID: 9848607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
    Prasad R; Verma SK; Sahai S; Kumar S; Jain A
    Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of mycobacterial resistance to four anti-tuberculosis drugs in pulmonary tuberculosis patients in the state of Qatar after the implementation of DOTS and a limited expatriate screening programme.
    Al-Marri MR
    Int J Tuberc Lung Dis; 2001 Dec; 5(12):1116-21. PubMed ID: 11769769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk of acquisition of RFP resistance out of INH resistant RFP susceptible tuberculosis].
    Yoshiyama T; Ito K; Ogata H; Aono A; Wada M
    Kekkaku; 2005 Jan; 80(1):9-14. PubMed ID: 15839057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.